227. Osler disease Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 56 Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

Drugs and their primary sponsors and trial info
AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung   
   Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
      2010   -   EUCTR2009-018049-19-AT   Austria;
Avastin   
   Hospices Civils de Lyon
      2014   -   EUCTR2013-004204-19-FR   France;
Bevacizumab   
   AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
      2008   -   EUCTR2010-020545-26-IT   Italy;
   Hanny Al-Samkari, MD
      2020   Phase 2   NCT04404881   United States;
   Hospices Civils de Lyon
      2017   Phase 3   NCT03227263   France;
      2014   Phase 2/Phase 3   NCT02106520   France;
      2011   Phase 1   NCT01507480   France;
   James Gossage
      2011   Phase 2   NCT01408030   United States;
   Medical University of Vienna
      2011   Phase 2   NCT01314274   Austria;
   Shandong Provincial ENT Hospital
      2021   Phase 4   ChiCTR2100043253   China;
   Stanford University
      2014   Phase 4   NCT02389959   United States;
   University of California, San Diego
      2009   Phase 2   NCT01397695   United States;
Bevacuzimab spray   
   University Hospital, Caen
      2014   Phase 1/Phase 2   NCT02157987   France;
Blood samples   
   Centre Hospitalier Universitaire Dijon
      2018   -   NCT03572556   France;
Dicynone   
   Asociación HHT España
      2017   Phase 2;Phase 4   EUCTR2016-003982-24-ES   Spain;
Doxycycline Hyclate   
   Unity Health Toronto
      2018   Phase 2   NCT03397004   Canada;
EMEA/H/C/000712   
   St. Antonius Hospital
      2019   Phase 2   EUCTR2019-003585-40-NL   Netherlands;
Estriol   
   James Gossage
      2011   Phase 2   NCT01408030   United States;
Ferrous sulphate 200mg oral tablet   
   Imperial College London
      2013   -   NCT01908543   United Kingdom;
Floseal   
   St. Michael's Hospital, Toronto
      2015   -   NCT02638012   Canada;
Gold   
   Beijing Institute of Otolaryngology
      2018   Phase 0   ChiCTR1900027420   China;
Itraconazole   
   St. Antonius Ziekenhuis
      2018   Phase 2   EUCTR2017-003272-31-NL   Netherlands;
Mupirocin   
   Hospital Italiano de Buenos Aires
      2017   Phase 3   NCT02963129   Argentina;
NaCl   
   Medical University of Vienna
      2011   Phase 2   NCT01314274   Austria;
Nintedanib 150 mg and 100 mg soft capsules   
   Hospices Civils de Lyon
      2020   Phase 2   NCT03954782   France;
Nintédanib   
   Hospices Civils de Lyon
      2019   Phase 2   EUCTR2019-002593-31-FR   France;
OCTREOTIDE ACETATE   
   Radboudumc
      2020   Phase 3   EUCTR2018-004179-11-DE   France;Germany;Italy;Netherlands;United Kingdom;
OCTREOTIDE ACETATO   
   RADBOUD UNIVERSITY MEDICAL CENTER
      2021   Phase 3   EUCTR2018-004179-11-IT   Denmark;France;Germany;Italy;Netherlands;United Kingdom;
OFEV   
   Hospices Civils de Lyon
      2019   Phase 2   EUCTR2019-002593-31-FR   France;
Octreotide   
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004327   -
Octreotide LAR   
   Radboud University
      2016   Phase 2   NCT02874326   Netherlands;
Octreotide a azione pronta 0,   
   RADBOUD UNIVERSITY MEDICAL CENTER
      2021   Phase 3   EUCTR2018-004179-11-IT   Denmark;France;Germany;Italy;Netherlands;United Kingdom;
PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung   
   Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
      2010   -   EUCTR2009-018049-19-AT   Austria;
Pazopanib   
   Cure HHT
      2019   Phase 2/Phase 3   NCT03850964   -
      2019   Phase 1/Phase 2   NCT03850730   -
Pegylated Interferon Alpha2b   
   Mayo Clinic
      2007   Phase 2   NCT00588146   United States;
Pomalidomide   
   The Cleveland Clinic
      2015   Phase 1   NCT02287558   United States;
Pomalidomide Oral Product   
   The Cleveland Clinic
      2019   Phase 2   NCT03910244   United States;
Propranolol treatment   
   University Hospital, Bordeaux
      2020   Phase 3   NCT04113187   France;
RVG 18236   
   Radboud University Medical Center
      2016   Phase 2   EUCTR2016-001340-19-NL   Netherlands;
Ranibizumab   
   University of California, San Diego
      2011   Phase 1   NCT01406639   United States;
SUB16402MIG   
   HOSPICES CIVILS DE LYON
      2009   -   EUCTR2008-006755-44-FR   France;
Sandostatin LAR   
   Radboud University Medical Center
      2016   Phase 2   EUCTR2016-001340-19-NL   Netherlands;
Sclerotherapy   
   University of Minnesota
      2011   Phase 1/Phase 2   NCT01408732   United States;
Sodium chloride   
   Hospices Civils de Lyon
      2017   Phase 3   NCT03227263   France;
Soy protein isolate   
   National Center for Research Resources (NCRR)
      1996   Phase 3   NCT00004654   -
Sporanox   
   St. Antonius Ziekenhuis
      2018   Phase 2   EUCTR2017-003272-31-NL   Netherlands;
Sterile saline   
   James Gossage
      2011   Phase 2   NCT01408030   United States;
Submucosal Bevacizumab   
   University of California, San Diego
      2010   Phase 2   NCT01402531   United States;
THALIDOMIDE CELGENE*28CPS   
   OSPEDALE POLICLINICO S. MATTEO
      2011   Phase 2   EUCTR2011-004096-36-IT   Italy;
TIMOLOL MALEATE   
   Hospices Civils de Lyon
      2015   Phase 2   EUCTR2015-000385-55-FR   France;
Tacrolimus (Advagraf)   
   St. Antonius Hospital
      2019   Phase 2   EUCTR2019-003585-40-NL   Netherlands;
Tacrolimus capsule (low-dose)   
   Unity Health Toronto
      2020   Phase 2   NCT04646356   Canada;
Tamoxifen   
   Rabin Medical Center
      2005   Phase 2   NCT00375622   Israel;
Thalidomide   
   IRCCS Policlinico S. Matteo
      2011   Phase 2   NCT01485224   Italy;
   Northport Veterans Affairs Medical Center
      2006   Phase 2   NCT00389935   United States;
Timolol Alcon collyre   
   Hospices Civils de Lyon
      2015   Phase 2   EUCTR2015-000385-55-FR   France;
Timolol Gel   
   Washington University School of Medicine
      2019   Phase 2   NCT04139018   United States;
Timolol nasal spray   
   Hospices Civils de Lyon
      2015   Phase 2   NCT02484716   France;
Topical timolol maleate   
   Unity Health Toronto
      2013   -   NCT01752049   Canada;
Tranexamic acid   
   University Hospital, Saarland
      2002   Phase 3   NCT01031992   Germany;
Vit D   
   St. Paul's Hospital, Canada
      2018   Phase 2   NCT03981562   Canada;